Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

REVEALED: Teva pharmaceutical indus earnings perspective return on capital employed | Rare Historical Photos

Benzinga Pro data, Teva Pharmaceutical Indus (NYSE:TEVA) reported Q4 sales of $4.10 billion. Earnings fell to a loss of $153.00 million, resulting in a 150.83% decrease from last quarter. Teva Pharmaceutical Indus reached earnings of $301.00 million and sales of $3.89 billion in Q3.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.